A Mount Sinai team reported a key design principle for next-generation mRNA therapeutics: detargeting mRNA expression away from hepatocytes can strengthen T-cell immunity in preclinical lymphoma models. The work, published in Nature Biotechnology, challenges the long-held view that strong T-cell priming depends on delivering mRNA primarily to dendritic cells. Using a microRNA-based approach to selectively silence mRNA expression in specific cell populations, the researchers found that turning off dendritic cell expression did not impair T-cell priming, while hepatocyte detargeting increased immune responses markedly. The study also indicates that non-immune cells can materially shape vaccine potency. For vaccine and immunotherapy developers, the results shift optimization priorities toward tissue targeting and expression control rather than focusing only on immune-cell delivery.